Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an announcement.
Australian Clinical Labs has an on-market share buy-back in place for its ordinary fully paid shares on the ASX, as part of a capital management program first notified in October 2025. The latest daily update shows that the company repurchased 81,675 shares on the previous trading day, taking total buy-backs to 6,056,533 shares, which incrementally reduces shares on issue and can enhance earnings per share for remaining investors.
The company’s regular buy-back disclosures indicate an ongoing commitment to returning capital to shareholders and actively managing its balance sheet. Continued execution of the buy-back may support the share price and signal management’s confidence in the company’s financial position and future prospects, with implications for valuation and ownership concentration over time.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.40 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is an Australian-listed healthcare company that operates pathology and diagnostic laboratory services, with its ordinary fully paid shares trading on the ASX under the code ACL. The company services healthcare providers and patients through its network of clinical laboratories, positioning it within the medical diagnostics and pathology testing sector.
Average Trading Volume: 689,086
Technical Sentiment Signal: Sell
Current Market Cap: A$390.1M
For an in-depth examination of ACL stock, go to TipRanks’ Overview page.